Aberrant activation of KIT results in MYC (MYC Proto-Oncogene, BHLH Transcription Factor)-dependent miR-29b down-regulation and an increase in Sp1 expression that results in KIT overexpression by NFkB transactivation, implicating deregulation of the protein–miRNA network Sp1/NFkB/HDAC/miR-29b in KIT-driven leukemia [89]. The gene discussed is MYC; the disease is leukemia.